Lorazepam
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Status Epilepticus
Conditions
Status Epilepticus
Trial Timeline
Nov 18, 2019 → Nov 15, 2023
NCT ID
NCT03905798About Lorazepam
Lorazepam is a pre-clinical stage product being developed by Pfizer for Status Epilepticus. The current trial status is completed. This product is registered under clinical trial identifier NCT03905798. Target conditions include Status Epilepticus.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03905798 | Pre-clinical | Completed |
| NCT02239380 | Phase 3 | Completed |
Competing Products
9 competing products in Status Epilepticus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CGM097 | Novartis | Phase 1 | 33 |
| BVS857 | Novartis | Phase 2 | 52 |
| Lorazepam | Pfizer | Phase 3 | 76 |
| levetiracetam (add-on) | UCB | Phase 2 | 49 |
| ESES treated with clobazam | Lundbeck | Pre-clinical | 20 |
| Epidiolex 100 mg/mL Oral Solution | Jazz Pharmaceuticals | Phase 1 | 30 |
| SAGE-547 | Supernus Pharmaceuticals | Pre-clinical | 18 |
| SAGE-547 | Supernus Pharmaceuticals | Phase 1/2 | 36 |
| SAGE-547 + Placebo | Supernus Pharmaceuticals | Phase 3 | 72 |